EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Show more
Location: 480 Pleasant Street, Watertown, MA, 02472, United States | Website: https://eyepointpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
647.5M
52 Wk Range
$3.91 - $13.99
Previous Close
$9.41
Open
$9.27
Volume
774,941
Day Range
$8.96 - $9.60
Enterprise Value
353.4M
Cash
318.2M
Avg Qtr Burn
-37.04M
Insider Ownership
3.46%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YUTIQ Details Chronic non-infectious uveitis | Approved Quarterly sales | |
DEXYCU Details Post-operative inflammation | Approved Quarterly sales | |
DURAVYU™ (vorolanib intravitreal insert) (EYP-1901) Details Macular degeneration, Wet age-related macular degeneration | Phase 3 Data readout | |
DURAVYU (EYP-1901) Details Diabetic macular edema | Phase 2 Update | |
EYP-1901 Details Non-proliferative diabetic retinopathy | Failed Discontinued |